Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.01−0.27 (-2.86%)
Close on Nov 18, 2026Market cap $579.84MP/E –Yield –
Cullinan Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Cullinan Therapeutics's shares outstanding was 58M at Sep 30, 2024. For fiscal 2023 it was 42M, down 10.9% from the year before.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 42M | -10.9% |
| FY2022 | Dec 31, 2022 | 47M | +8.3% |
| FY2021 | Dec 31, 2021 | 43M | +116.6% |
| FY2020 | Dec 31, 2020 | 20M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | 58M | +36.5% |
| Q2 FY2024 | Jun 30, 2024 | 55M | +37.8% |
| Q1 FY2024 | Mar 31, 2024 | 43M | +5.7% |
| Q4 FY2023 | Dec 31, 2023 | 43M | -8.6% |
| Q3 FY2023 | Sep 30, 2023 | 43M | -6.3% |
| Q2 FY2023 | Jun 30, 2023 | 40M | -13.9% |
| Q1 FY2023 | Mar 31, 2023 | 41M | -8.4% |
| Q4 FY2022 | Dec 31, 2022 | 47M | +10.0% |
| Q3 FY2022 | Sep 30, 2022 | 46M | +5.0% |
| Q2 FY2022 | Jun 30, 2022 | 46M | +7.1% |
| Q1 FY2022 | Mar 31, 2022 | 44M | +5.8% |
| Q4 FY2021 | Dec 31, 2021 | 43M | +100.8% |
| Q3 FY2021 | Sep 30, 2021 | 43M | +120.3% |
| Q2 FY2021 | Jun 30, 2021 | 43M | +120.7% |
| Q1 FY2021 | Mar 31, 2021 | 42M | +123.9% |
| Q4 FY2020 | Dec 31, 2020 | 21M | – |
| Q3 FY2020 | Sep 30, 2020 | 20M | – |
| Q2 FY2020 | Jun 30, 2020 | 20M | – |
| Q1 FY2020 | Mar 31, 2020 | 19M | – |
See a number that looks wrong?